- Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drugRoyalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca-partnered med.Fierce Biotech · 3d ago↗ source
- From Big Pharma to specialty: why moving closer to the patient changes everythingWorking at a Big Pharma has its benefits, but there are limitations too. SERB Pharmaceuticals’ Thomas Kolaras discusses how moving to a midsize company creates new opportunities for sharpened think…BioSpace · 3d ago↗ source
- Celldex ends skin disease program after failing phase 2 testA phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech to end development in the indication and raising doubts about an upcoming e…